About ACADIA Pharmaceuticals Inc. - Common Stock (ACAD)
Acadia Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapeutics to address unmet medical needs in central nervous system disorders. The company specializes in creating treatments for conditions such as schizophrenia and Parkinson's disease, leveraging its expertise in neuroscience to enhance the quality of life for patients. Through a combination of research, clinical development, and regulatory advocacy, Acadia aims to deliver targeted therapies that address the root causes of these complex conditions, while striving to improve overall patient outcomes in the neurological space. Read More
Acadia's Phase 3 Compass Prader-Willi syndrome trial failed to meet endpoints, but the company projects $1 billion in sales in 2025 and highlights a strong pipeline outlook.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbetocin (ACP-101) in patients with hyperphagia in Prader-Willi syndrome (PWS). Intranasal carbetocin did not demonstrate a statistically significant improvement over placebo on the study’s primary endpoint, change from baseline to Week 12 on the Hyperphagia Questionnaire for Clinical Trials (HQ-CT), nor was there separation from placebo on any secondary endpoint. The safety and tolerability profile of intranasal carbetocin was consistent with previous clinical trials, showing a low rate of adverse events.
ACADIA Pharmaceuticals (ACAD) shows strong technical momentum with a high-quality consolidation pattern, signaling a potential breakout opportunity for traders.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the journal Developmental Medicine and Child Neurology published interim results from the caregiver-reported observational online, open-label, ongoing LOTUS study evaluating effectiveness and tolerability outcomes in patients with Rett syndrome who are prescribed DAYBUE® (trofinetide) under routine clinical care in the U.S. Findings included reported improvements in symptoms of Rett syndrome, with early insights into managing gastrointestinal (GI) symptoms in the real world among patients receiving up to 12 months of treatment with DAYBUE.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on September 4, 2025, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 161,676 shares of common stock and 49,363 restricted stock units (“RSUs”) to eighteen new employees under Acadia’s 2024 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
ACADIA Pharmaceuticals (ACAD) offers strong growth metrics and a reasonable valuation within the biotech sector, making it a top affordable growth stock pick.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Konstantina (“Tina”) Katcheves as Senior Vice President, Chief Business and Strategy Officer. In this role, Tina will lead Acadia’s business development and corporate strategy and serve as a member of the Company’s Executive Leadership Team, reporting to Catherine Owen Adams, Chief Executive Officer of Acadia.
ACADIA Pharmaceuticals (ACAD) offers strong growth, fair valuation, and solid financial health, making it a top pick for the Affordable Growth investment strategy.
ACADIA Pharmaceuticals (ACAD) shows strong growth fundamentals with rising revenue, EPS, and solid margins, plus a bullish technical breakout, making it a promising stock pick.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on August 5, 2025, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 63,477 shares of common stock and 49,377 restricted stock units (“RSUs”) to twenty-six new employees under Acadia’s 2024 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13, 2025 at 2:30 p.m. Eastern Time.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Scott Cenci as Senior Vice President, Chief Information and Data Officer. In this role, Scott will lead Acadia’s digital transformation including technology, data and AI strategy and will serve as a member of the company’s Executive Leadership Team, reporting to Catherine Owen Adams, Chief Executive Officer of Acadia.
ACADIA Pharmaceuticals (ACAD) offers strong growth, solid profitability, and fair valuation, making it a top pick for investors seeking affordable growth in biotech.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter financial results on Wednesday, August 6, 2025, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on August 6, 2025, at 4:30 p.m. Eastern Time.
